Search

Displaying results 741 - 750 of 1101 in total
  1. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

  2. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages

  3. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030

  4. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  5. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). … [L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular

  6. Drug

    Collagenase clostridium histolyticum

    go.drugbank.com/drugs/DB00048
    ApprovedInvestigational

    Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical ...

  7. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid sig...

  8. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...

    Mixtures: Nu-chlorax Capsules USP
  9. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    Sodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of gamma-Hydroxybutyric acid, an endogenous cerebral inhibitory n...

  10. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...